RNA Outsourcing Resources

1. Automated Cryo‑Processed Leukapheresis For CAR‑T Manufacturing 3/30/2026

   Automated, closed cryo‑processing of leukapheresis preserves cell quality and functionality, enabling flexible, reproducible starting material for both autologous and allogeneic CAR‑T manufacturing.

2. Navigating Challenges In Progressing Breakthrough RNA Therapeutics 5/14/2024

   RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.

3. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

   Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

4. Minimizing Volume Requirements, Turnaround Time For Compendial Testing 10/30/2025

   Effectively applying compendial testing to cell and gene therapy products requires strategic test ordering and specialized micro-equipment to manage limited volume and accelerate turnaround time.

5. The Shift Toward Flexible FSP Models 11/13/2025

   Flexible FSP models are reshaping clinical outsourcing by offering sponsors scalable, cost-predictable partnerships that preserve control, enhance quality, and support long-term strategic goals.

6. How Global Supply Chain Centers Amplify CGT Program Growth 10/20/2025

   Consolidating logistics, cryopreservation, and storage eliminates handoffs and risk. This single-platform approach creates the consistency needed for global compliance and growth.

7. How To Choose The Right CRO For Your Clinical Trial 3/28/2025

   Selecting the right Contract Research Organization (CRO) is critical for the success of a clinical trial. This article outlines essential factors to consider during the selection process.

8. Building Stability Through Integrated Cryopreservation 3/30/2026

   Early integration of standardized, GMP-aligned cryopreservation improves consistency, documentation, and scalability in advanced therapy programs as they progress toward regulatory submissions.

9. The Future Of CGT: Phase-Appropriate Plasmid DNA Manufacturing 10/16/2025

   Effective CGT development hinges on phase-appropriate manufacturing. Matching manufacturing rigor to the clinical phase ensures the right quality at the right time while reducing costs and accelerating timelines.

10. Mapping The Future: Q&A With Mark Sawicki, Ph.D., On 2025 Trends In CGT 2/25/2025

    Learn how you can stay ahead of the evolving cell and gene therapy landscape by leveraging innovative solutions to support the continued growth and success of therapies in 2025 and beyond.